Weight Loss Medication
60 articles on Weight Loss Medication, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter
Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.
8 min read
Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss
Researchers analyzed nearly 877,000 patients and found a significant link between GLP-1 receptor agonists and sensory disturbances.
8 min read
I Lost 5 Stone on Mounjaro — But Now I’ve Had Enough
Natalie Lavergne transformed her health and lost 5 stone using Mounjaro, but now plans to switch to the Wegovy pill. Discover the medical realities of stopping weight loss medication.
8 min read
Bitter Hops Extract Supplement for Weight Loss
A recent study suggests a bitter hops extract supplement, Amarasate, could aid fat loss and preserve muscle mass, offering a potential alternative or complementary approach to GLP-1 medications.
8 min read
GP's Verdict on GLP-1 Tablet Rollout: A Damp Squib?
A UK GP shares his observations on the limited uptake of new GLP-1 weight loss tablets, suggesting patient familiarity with injections and daily dosing challenges may be factors.
8 min read
Eli Lilly Prepares FDA Run for ‘Triple-G’ Weight Loss Drug With Phase 3 Data
Eli Lilly has announced positive Phase 3 results for retatrutide, positioning the triple-agonist drug for an FDA filing in 2027 with substantial weight loss outcomes.
7 min read
Ozempic Lowers Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
A new 60-week clinical trial reveals that semaglutide continues to reduce calorie consumption significantly, even when subjective hunger sensations return to baseline levels.
7 min read
Meghan McCain Responds to 'Old and Ugly' Comments by Rejecting Ozempic
Meghan McCain has publicly pushed back against harsh online comments about her appearance, emphasizing her commitment to natural aging and rejecting the use of weight-loss medications like Ozempic.
6 min read
The Most Confronting Side Effect of Wegovy Weight Loss Wasn't Physical
While physical side effects of Wegovy are well-documented, one patient's experience highlights a profound, non-physical challenge: the shift in how society perceives and treats individuals after significant weight loss.
7 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell discusses her 30kg weight loss using Mounjaro, the subsequent skin concerns, and the mental health benefits of GLP-1 therapy.
6 min read
Novo Nordisk Sues Eli Lilly Over Which GLP-1 Sheds the Most Pounds
Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising regarding the comparative weight loss efficacy of Zepbound and Wegovy. The dispute centers on dosage comparisons and clinical trial data interpretation.
8 min read
The New Drug Melting Body Fat From 38% To 22% — And The Side Effects Patients Are Ignoring
A detailed look at the case of Gary Anderton, who achieved significant weight loss using unregulated peptides, and the critical safety risks associated with this trend.
8 min read
Compounded Ozempic and Zepbound Still Widely Available After Shortages End
Despite the FDA declaring an end to drug shortages for popular weight loss medications, a new study finds compounded versions remain easily accessible. Understanding the safety implications and regulatory landscape is crucial for patient health.
8 min read
Novo Nordisk Sues Eli Lilly, Alleging Misleading Advertising of Obesity Drugs
Novo Nordisk has filed a lawsuit against Eli Lilly in New Jersey, claiming deceptive advertising regarding GLP-1 and dual-agonist weight loss medications.
7 min read
The Workforce Runs on Weight Loss Drugs? Employees on GLP-1s Take Fewer Sick Days
A new study reveals significant reductions in long-term sick leave for workers taking GLP-1 medications, offering insights into workplace productivity and long-term health savings.
10 min read
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising Claims in Legal Battle
Novo Nordisk has filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising regarding GLP-1 weight loss medications.
7 min read
Ozempic Maker Novo Nordisk Sues Eli Lilly Over 'Materially Misleading' Ads
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging deceptive advertising regarding weight-loss drugs. This legal battle highlights the intense competition between semaglutide and tirzepatide.
9 min read
Medicare's New GLP-1 Weight-Loss Drug Program: What to Know
Medicare is launching a new pilot program to increase access to GLP-1 medications for weight loss, offering a $50 monthly copay for eligible beneficiaries. This marks a significant step in covering obesity as a medical condition.
9 min read
Semaglutide Greenlit for MASH Liver Disease Treatment
The MHRA has granted conditional approval for semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
7 min read
Plus-Size Swimsuit Model on Inclusivity Amidst GLP-1 Medications
Plus-size model Hunter McGrady shares her concerns about a perceived decline in fashion inclusivity, particularly in the context of the growing popularity of GLP-1 weight loss medications.
7 min read
Peptide Hype: Do They Live Up to the Claims for Skin and Wellness?
From skincare routines to GLP-1 weight loss medications, peptides are everywhere. But do they deliver on their promises for skin health, longevity, and recovery? This article delves into the science and the trend.
9 min read
Dr. Reddy's Generic Ozempic Supplies Delayed on API Issue
Dr. Reddy's Laboratories has paused commercial production of generic semaglutide following quality concerns with the active ingredient. Here is what patients need to know about the delay and what it means for access to GLP-1 therapy.
8 min read
The Overlooked Nutrition Risks of Ozempic and Wegovy
New research from UCL and Cambridge highlights critical nutrition gaps in GLP-1 therapy. Discover the risks of muscle loss and deficiencies, and how to manage them safely.
8 min read
People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less
New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.
8 min read
The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
6 min read
GLP-1 Medications for Obesity: Experts See a Broader Revolution Ahead
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
6 min read
Ozempic's Oral Twin: A Needle-Free Weight Loss Revolution Arrives?
A new era in weight management may be dawning as an oral medication, mirroring the efficacy of popular injectables like Ozempic, is poised for approval. This development promises a more accessible and convenient path to weight loss for millions.
7 min read
Wegovy and the Wedding Dress: The Hidden Costs of Rapid Weight Loss
Prescription weight loss drugs are becoming a wedding staple, but medical experts warn of serious side effects and ethical concerns behind the trend.
9 min read
Ozempic Generics Recall: Why Cheap Semaglutide Copies Are Being Pulled
India's booming generic semaglutide market faces a credibility crisis as major manufacturers recall batches over quality concerns. Discover the implications for patient safety and treatment continuity.
9 min read
Ozempic & Wegovy Safety: The Yale Study on Online Prescribing
A recent JAMA study reveals significant gaps in medical oversight for online GLP-1 prescriptions. Discover the risks and how to ensure safe access to weight loss medications.
7 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Ozempic, Wegovy, Mounjaro: How Long Do GLP-1s Stay in Your System?
Curious about how long Ozempic, Wegovy, Mounjaro, or other GLP-1 medications stay in your system after your last dose? This comprehensive guide explores the science behind their elimination and what factors influence their duration.
7 min read
Svemia Approved: What Canada's New Semaglutide Generic Means for You
Canada's Health Department has cleared Apotex's Svemia, marking a major milestone for generic semaglutide availability and weight loss treatment access.
7 min read
Ozempic, Wegovy, Mounjaro: How Do They Affect Mental Health?
New research sheds light on the neuropsychiatric effects of popular weight loss medications like semaglutide and tirzepatide. Discover how these treatments may influence anxiety, depression, and other mental health outcomes.
7 min read
Beyond the Scale: Navigating GLP-1s for Older Adults
As GLP-1 medications become more accessible, older adults are asking: 'Am I too old?' This guide explores the nuances of using these powerful drugs for weight loss in seniors, emphasizing health over age.
7 min read
Wegovy & Mounjaro: Navigating Medicare's New Path to Weight Loss
For years, Medicare's stance on GLP-1 medications for weight loss was a firm 'no.' However, a significant shift is underway. Discover how the new 'Bridge' program opens doors to crucial weight management tools like Wegovy and Mounjaro, and what you need to know.
6 min read
Mounjaro Access Expands: Northern Ireland Launches New Weight Loss Service
Northern Ireland is set to launch a £5 million Regional Obesity Management Service, improving access to Mounjaro and lifestyle support for adults struggling with obesity.
8 min read
Ozempic Culture: Why Medical Weight Loss Needs Better Guardrails
As semaglutide medications become ubiquitous, we must balance their life-saving cardiovascular benefits with the dangers of normalizing extreme thinness and disordered eating behaviors.
7 min read
Zepbound vs. Wegovy: New Meta-Analysis Reveals Top Weight Loss Drug
A comprehensive meta-analysis from the University of Georgia has finally put major weight loss medications head-to-head. Here is what the data says about Zepbound, Wegovy, and Saxenda.
8 min read
Beyond Ozempic: Why Zepbound Might Be the Heavyweight Champion for Weight Loss
A comprehensive review of the latest clinical data comparing Tirzepatide, Semaglutide, and Liraglutide to determine the most effective option for significant weight reduction.
8 min read
Ozempic & Wegovy: Surprising Bone Health Benefit Uncovered
While GLP-1 agonists like Ozempic and Wegovy are celebrated for weight loss and blood sugar control, a recent study suggests a surprising benefit: improved bone health and a reduced risk of fractures in adults with Type 2 diabetes.
7 min read
Ozempic and Male Fertility: Can Semaglutide Boost Sperm Quality?
Emerging research indicates that GLP-1 medications, including Ozempic and Mounjaro, may offer unexpected benefits for male reproductive health by addressing underlying metabolic issues.
7 min read
Semaglutide and Male Fertility: New Study Reveals Testosterone Boost
Can GLP-1 medications like Ozempic or Wegovy improve male fertility? A new study indicates potential benefits for testosterone and sperm health, but what does this mean for patients?
7 min read
GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight
The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.
6 min read
GLP-1s & Telehealth: Navigating Risks and Ensuring Safety
The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.
6 min read
Alli Weight Loss Pill: FDA Flags Serious Kidney Risks
The Food and Drug Administration (FDA) has issued a new warning regarding potential serious kidney complications associated with Alli, the sole over-the-counter weight loss medication available in the United States. The drug's label has been updated to reflect these risks, urging caution for consumers.
8 min read
Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds
A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.
7 min read
Ozempic, Wegovy, Mounjaro: Why Rhode Island Medicaid Must Cover Obesity Meds
Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.
6 min read
Alli's Kidney Risk: FDA Updates Label for Over-the-Counter Weight Loss Pill
The FDA has issued a critical update to the drug facts label for Alli, the only over-the-counter weight loss medication available in the U.S. The changes highlight rare but potentially severe kidney-related side effects, prompting new warnings for consumers.
7 min read
Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39
The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.
7 min read
Wegovy Pill Launch: Why 80% of Patients Are Choosing Oral Semaglutide
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
9 min read
Beyond the Dose: Why Some GLP-1s Fall Short & What It Means
A groundbreaking Stanford study reveals a genetic reason why approximately 10% of individuals don't respond as expected to GLP-1 receptor agonists, impacting treatments for diabetes and weight loss.
7 min read
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
7 min read
Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym
For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.
6 min read
Wegovy and Zepbound on Medicare: What the $50 Co-Pay Means for Your Health
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
7 min read
Semaglutide and Pregnancy: Understanding New Risks and Weight Rebound
A recent national database study reveals significant obstetric risks associated with semaglutide exposure before and during pregnancy, highlighting the importance of the weight rebound effect.
7 min read
Beyond Ozempic: A New Pill Targets Fat Metabolism Without Appetite Loss
A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.
7 min read
Beyond the Needle: Why Wegovy Alone Can't Cure New Zealand's Obesity Crisis
As New Zealand considers public funding for Wegovy, experts warn that medication alone cannot solve the obesity epidemic driven by complex environmental and social factors.
8 min read
Glenmark's Semaglutide Launch: What It Means for Global Weight Loss Access
Glenmark Pharmaceuticals outlines an ambitious FY27 growth strategy, highlighting significant expansion in the GLP-1 segment with GLIPIQ. Discover how this impacts global access to Semaglutide and weight loss therapies.
7 min read